Delivering Innovative Renal
and Vascular Therapies
Developing novel, first-in-class pharmaceuticals to address the
medical needs of patients with renal and vascular diseases
Addressing Vascular Access
Failure in Hemodialysis
Improving vascular access outcomes would provide a
lasting benefit to hemodialysis patients
Learn More
About PRT-201
An investigational drug for the reduction of vascular
access failure for patients receiving hemodialysis
We are a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with renal and vascular diseases. Proteon Therapeutics’ first drug candidate, PRT-201, is a locally-acting recombinant human elastase that fragments elastin fibers in blood vessel walls. PRT-201 has received fast track and orphan drug designations from the FDA and orphan medicinal product designation from the European Commission for hemodialysis vascular access indications. Proteon is investigating whether elastase could be used as a treatment to dilate arteries and veins and to reduce neointimal hyperplasia in settings where such effects would result in a medical benefit.
